基于《中国医疗机构药品评价与遴选快速指南(第二版)》的原研钠-葡萄糖协同转运蛋白2抑制剂综合评价  

Comprehensive Evaluation of Original Research Sodium-glucose Transporters 2 Inhibitors Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)

作　　者：计成[1] 周兵 朱鹏里 王超[4] 钟询龙[5] 沈爱宗 张弋[4] 王若伦[5] 葛卫红[1] 董占军[6] 赵志刚[7] JI Cheng;ZHOU Bing;ZHU Pengli;WANG Chao;ZHONG Xunlong;SHEN Aizong;ZHANG Yi;WANG Ruolun;GE Weihong;DONG Zhanjun;ZHAO Zhigang(Department of Pharmacy,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210008,China;Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,Nanjing 210008,China;Department of Pharmacy,the First Affiliated Hospital of University of Science and Technology of China,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Department of Pharmacy,Tianjin First Central Hospital,Tianjin 300192,China;Department of Pharmacy,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China;Department of Pharmacy,Hebei General Hospital,Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang 050051,China;Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008 [2]南京中医药大学鼓楼临床医学院,南京210008 [3]中国科学技术大学附属第一医院(安徽省立医院)药学部,合肥230001 [4]天津市第一中心医院药学部,天津300192 [5]广州医科大学附属第二医院药学部,广州510260 [6]河北省人民医院药学部,河北省临床药学重点实验室,石家庄050051 [7]首都医科大学附属北京天坛医院,北京100050

出　　处：《医药导报》2025年第2期251-258,共8页Herald of Medicine

摘　　要：目的基于《中国医疗机构药品评价与遴选快速指南(第二版)》,对原研钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂进行临床综合评价,以期为不同患者制定个体化治疗方案提供参考和依据,优化SGLT-2抑制剂类降糖药临床使用路径。方法收集整理参评药物相关真实世界研究、随机对照试验、Meta分析/系统综述、药品临床使用指南、专家共识及药品说明书等文献资料,依据SGLT-2抑制剂药品特点修改评价维度,整体从药学特性、有效性、安全性、经济性及其他属性共5个维度对纳入的药品进行综合评价。结果所有参评原研SGLT-2抑制剂评价得分均>75分,其中达格列净片得分最高,为84.6分;脯氨酸恒格列净得分最低,为75.1分。结论5种原研SGLT-2抑制剂均表现出良好的临床效用,区别在于参评原研药品在临床使用中存在不同的优势区间。达格列净临床效用最理想,临床使用应更加安全有效。可能由于上市时间短,循证依据不足的等原因,脯氨酸恒格列净相比于其他参评药品临床使用优势不明显。Objective In order to provide a better reference and basis for the selection of reasonable hypoglycemic drugs for clinical treatment,the study conducted a comprehensive clinical evaluation of the innovator sodium-glucose transporters 2(SGLT-2)inhibitors,based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition).Methods The real-world studies,randomized controlled trials,Meta-analysis/systematic review,drug clinical use guidelines,expert consensus and drug description evaluation evidence were collected,and the included drugs were assigned and evaluated from five dimensions:pharmaceutical characteristics,efficacy,safety,economy and other attributes.Results All SGLT-2 inhibitors had evaluation scores above 75,with dagaglifloztin tablets having the highest score of 84.6,and canaglifloztin having the lowest score of 75.1.Conclusions All five original SGLT-2 inhibitors showed good clinical utility,the difference is that the participating original drugs have different advantageous intervals in clinical use.The results show that dagliflozin has the most ideal clinical utility,and its clinical use should be safer and more effective.Due to the short time on the market and insufficient evidence-based reasons,the advantages of clinical use of proline hemegliflozin are not obvious compared with other evaluated drugs.

关 键 词：钠-葡萄糖协同转运蛋白-2抑制剂 达格列净 恩格列净 卡格列净 艾托格列净 脯氨酸恒格列净 综合评价 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]